Literature DB >> 16617319

Toll-like receptors mediate proliferation and survival of multiple myeloma cells.

J Bohnhorst1, T Rasmussen, S H Moen, M Fløttum, L Knudsen, M Børset, T Espevik, A Sundan.   

Abstract

Multiple myeloma (MM) is an incurable B-cell malignancy characterized by accumulation of malignant plasma cells in bone marrow (BM) and recurrent or persistent infections. Toll-like receptors (TLRs) are essential in the host defense against infections and today 10 human TLRs (TLR1-TLR10) and one TLR-homolog (RP105) have been characterized. B cells express several TLRs (mainly TLR1, 6, 7, 9, 10 and RP105) and TLR-initiated responses in B cells include proliferation, anti-apoptosis effect and plasma cell (PC) differentiation. The present study was designed to analyze the role of TLRs in MM. We show that frequent expressions of TLRs were detected in cell lines from MM patients (minimum six TLRs in each). In comparison, only few TLRs (mainly TLR1 and or RP105) were found expressed in PCs from BM of healthy donors. In addition, TLR-specific ligands induce increased proliferation and survival of the MM cell lines, partially due to an autocrine interleukin-6 production. Importantly, we demonstrate that also PC from MM patients proliferates in response to TLR-specific ligands. In conclusion, TLR-ligands may contribute to increased growth and survival of MM cells in MM patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16617319     DOI: 10.1038/sj.leu.2404225

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  44 in total

1.  RNA interference screening identifies lenalidomide sensitizers in multiple myeloma, including RSK2.

Authors:  Yuan Xiao Zhu; Hongwei Yin; Laura A Bruins; Chang-Xin Shi; Patrick Jedlowski; Meraj Aziz; Chris Sereduk; Klaus Martin Kortuem; Jessica E Schmidt; Mia Champion; Esteban Braggio; A Keith Stewart
Journal:  Blood       Date:  2014-11-13       Impact factor: 22.113

Review 2.  Toll-like receptors and cancer.

Authors:  Seth Rakoff-Nahoum; Ruslan Medzhitov
Journal:  Nat Rev Cancer       Date:  2008-12-04       Impact factor: 60.716

Review 3.  Multiple myeloma.

Authors:  S Vincent Rajkumar
Journal:  Curr Probl Cancer       Date:  2009 Jan-Feb       Impact factor: 3.187

Review 4.  Toll-like receptors--sentries in the B-cell response.

Authors:  Isabelle Bekeredjian-Ding; Gaetan Jego
Journal:  Immunology       Date:  2009-11       Impact factor: 7.397

Review 5.  Toll-like receptors: lessons to learn from normal and malignant human B cells.

Authors:  David Chiron; Isabelle Bekeredjian-Ding; Catherine Pellat-Deceunynck; Régis Bataille; Gaëtan Jego
Journal:  Blood       Date:  2008-06-30       Impact factor: 22.113

6.  Plasma cell toll-like receptor (TLR) expression differs from that of B cells, and plasma cell TLR triggering enhances immunoglobulin production.

Authors:  Marcus Dorner; Simone Brandt; Marianne Tinguely; Franziska Zucol; Jean-Pierre Bourquin; Ludwig Zauner; Christoph Berger; Michele Bernasconi; Roberto F Speck; David Nadal
Journal:  Immunology       Date:  2009-12       Impact factor: 7.397

7.  Extracellular HSP70-peptide complexes promote the proliferation of hepatocellular carcinoma cells via TLR2/4/JNK1/2MAPK pathway.

Authors:  Yi Zhe; Yan Li; Dan Liu; Dong-Ming Su; Jin-Gang Liu; Hang-Yu Li
Journal:  Tumour Biol       Date:  2016-08-04

Review 8.  A cytokine-mediated link between innate immunity, inflammation, and cancer.

Authors:  Wan-Wan Lin; Michael Karin
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

Review 9.  Toll-like receptor signaling in cell proliferation and survival.

Authors:  Xinyan Li; Song Jiang; Richard I Tapping
Journal:  Cytokine       Date:  2009-09-22       Impact factor: 3.861

Review 10.  Endotoxin and cancer.

Authors:  Jessica I Lundin; Harvey Checkoway
Journal:  Environ Health Perspect       Date:  2009-05-07       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.